抽象的
囊性纤维化(CF)是最常见的致死性遗传性疾病,具有高加索人的常染色体隐性遗传。大多数CF患者患有慢性呼吸道感染与机会致细菌病原体假单胞菌铜绿假单胞菌。到目前为止,临床医生之间没有共识,迄今为止在CF患者中针对针对铜绿假单胞菌的抗生素治疗。在这方面的34个欧洲专家小组给出的情况下,在此背景下,在这方面提出了24个重要问题的共识答案。解决和答复的问题是:CF中的铜绿假单胞菌肺部定植的诊断;铜绿假单胞菌对CF患者临床状态的影响;对铜绿假单胞菌对抗生素的敏感性的评估以及这些结果对临床医生的重要性;单一疗法的使用与组合治疗;微生物抗性的发展;实现最佳气道浓度; The effects of subinhibitory concentrations of antibiotics on P. aeruginosa; Statements on the pharmacokinetics of antibiotics in CF patients; Recommendations for doses and dosing intervals and length of treatment regimens; and Toxic side effects due to repeated antibiotic therapy was addressed. The expert panel answered further questions on the use of fluoroquinolones in children with CF, on the administration of nebulized antibiotics and whether prevention of P. aeruginosa lung colonization is possible in CF using antibiotic therapy. Problems of antibiotic therapy at home and in the hospital were addressed, a consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations. Finally, the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in cystic fibrosis patients were addressed and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended.